- Xylem recently expanded its water treatment offerings through commercial partnerships with Gross-Wen Technologies for integrated industrial wastewater solutions and with Moleaer to introduce nanobubble technology to surface water restoration projects, while also announcing executive leadership changes effective July 1, 2026, including new EVP roles for Measurement and Control Solutions and Applied Water.
- These moves highlight Xylem’s emphasis on higher-value treatment technologies and experienced leadership to deepen its position in nutrient removal and ecological water restoration markets.
- We’ll now examine how Xylem’s expanded industrial wastewater partnership with Gross-Wen Technologies may influence the company’s longer-term investment narrative.
We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
Xylem Investment Narrative Recap
To own Xylem, you need to believe in long term demand for advanced water infrastructure, digital monitoring and higher value treatment technologies, supported by a solid backlog and recurring revenue potential. The Gross Wen and Moleaer partnerships, together with new leadership in Measurement and Control Solutions and Applied Water, appear directionally aligned with that story but do not meaningfully change the near term focus on funding cycles and execution risk around large integrations such as Evoqua.
The Gross Wen Technologies partnership is especially relevant here because it extends Xylem’s reach in industrial wastewater and nutrient removal, directly reinforcing the catalyst around expanding higher value treatment solutions. By pairing Xylem’s anaerobic treatment with Gross Wen’s Revolving Algal Biofilm platform, the company gains a more complete offering for tightening nutrient regulations, which may support its aim of deepening recurring, compliance driven revenue streams tied to industrial customers.
Yet investors should also weigh how concentrated exposure to public funding and large project cycles could interact with...
Read the full narrative on Xylem (it's free!)
Xylem's narrative projects $10.3 billion revenue and $1.5 billion earnings by 2029. This requires 4.2% yearly revenue growth and about a $0.5 billion earnings increase from $981.0 million today.
Uncover how Xylem's forecasts yield a $150.65 fair value, a 29% upside to its current price.
Exploring Other Perspectives
While the Gross Wen deal speaks to growth in higher value treatment, the most pessimistic analysts were assuming only about US$9.9 billion revenue and US$1.5 billion earnings by 2029, so you should expect that some of those views may shift as this and similar announcements play through the numbers.
Explore 4 other fair value estimates on Xylem - why the stock might be worth just $123.56!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Xylem research is our analysis highlighting 5 key rewards that could impact your investment decision.
- Our free Xylem research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Xylem's overall financial health at a glance.
Interested In Other Possibilities?
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
- Find 42 companies with promising cash flow potential yet trading below their fair value.
- Uncover the next big thing with 22 elite penny stocks that balance risk and reward.
- Outshine the giants: these 15 early-stage AI stocks could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com